BCRF unveils a $100M fund, awarding its first investment to AI mammography company Clairity Inc.
Key Details
- 1Breast Cancer Research Foundation (BCRF) launches a new $100M venture fund to accelerate innovation.
- 2Initial $23 million raised, $11 million from donors Karen and Rob Hale.
- 3First investment goes to Clairity Inc., founded by radiologist Connie Lehman.
- 4Clairity Breast uses AI to analyze mammograms and predict 5-year breast cancer risk.
- 5Clairity Breast was the first AI-powered breast cancer risk prediction tool to win FDA De Novo Authorization.
- 6The solution is now part of national guidelines for breast cancer risk assessment.
Why It Matters
This marks one of the largest targeted investments into AI-driven breast imaging, backing scalable risk prediction in routine mammography. The fund's support could accelerate the adoption of AI-powered tools in radiology, helping address early detection and access disparities.
Source
Radiology Business
Related News
•Radiology Business
New AI Flags Uncertainty in Breast Cancer Imaging Predictions
University of Pittsburgh researchers developed an AI model that quantifies uncertainty in breast cancer diagnostic predictions to enhance trustworthiness.
•Cardiovascular Business
FDA Clears Elucid's AI-Driven FFR-CT Solution for Cardiac Imaging
Elucid's FFR-IQ, an AI-powered noninvasive FFR-CT tool, receives FDA clearance for clinical use.
•Radiology Business
FDA Approves SimBioSys AI Tool for Breast Cancer Risk via MRI
SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.